NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited (NSB.AX) Financial Performance & Income Statement Overview
Review NeuroScientific Biopharmaceuticals Limited (NSB.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
NeuroScientific Biopharmaceuticals Limited (NSB.AX) Income Statement & Financial Overview
Explore comprehensive income reports for NeuroScientific Biopharmaceuticals Limited NSB.AX, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.79M | $1.16M |
| Cost of Revenue | $48906.00 | $42431.00 | $27852.00 | $30002.00 |
| Gross Profit | -$48906.00 | -$42431.00 | $3.77M | $1.13M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.99 | $0.97 |
| R&D Expenses | $245220.00 | $247239.00 | $1.11M | $2.91M |
| SG&A Expenses | $451028.00 | $1.02M | $707246.00 | $1.33M |
| Operating Expenses | $696248.00 | $1.27M | $1.82M | $4.24M |
| Total Costs & Expenses | $745154.00 | $1.31M | $1.85M | $4.27M |
| Interest Income | $88226.00 | $90710.00 | $51265.00 | $56264.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $48906.00 | $42431.00 | $27852.00 | $30002.00 |
| EBITDA | $1.60M | -$1.19M | $2.02M | -$3.03M |
| EBITDA Ratio | $0.00 | $0.00 | -$0.48 | -$3.66 |
| Operating Income | -$745154.00 | -$1.31M | -$1.85M | -$4.27M |
| Operating Income Ratio | $0.00 | $0.00 | -$0.49 | -$3.69 |
| Other Income/Expenses (Net) | $2.30M | $81244.00 | $46531.00 | $56264.00 |
| Income Before Tax | $1.55M | -$1.23M | $1.99M | -$3.06M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.52 | -$2.64 |
| Income Tax Expense | $4.00 | -$1.00 | -$2.00 | -$2.00 |
| Net Income | $1.55M | -$1.23M | $1.99M | -$3.06M |
| Net Income Ratio | $0.00 | $0.00 | $0.52 | -$2.64 |
| EPS | $0.01 | -$0.009 | $0.01 | -$0.02 |
| Diluted EPS | $0.01 | -$0.009 | $0.01 | -$0.02 |
| Weighted Avg Shares Outstanding | $144.60M | $144.60M | $143.47M | $143.47M |
| Weighted Avg Shares Outstanding (Diluted) | $144.60M | $144.60M | $143.47M | $143.47M |
Over the past four quarters, NeuroScientific Biopharmaceuticals Limited demonstrated steady revenue growth, increasing from $1.16M in Q2 2023 to $0.00 in Q4 2024. Operating income reached -$745154.00 in Q4 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $1.60M, reflecting operational efficiency. Net income rose to $1.55M, with EPS at $0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan